vancomycin / Generic mfg. - LARVOL DELTA

Culture-Proven Haemophilus influenzae Endophthalmitis After Intravitreal Topotecan for Retinoblastoma. (PubMed, J Vitreoretin Dis) - "Urgent 23-gauge pars plana vitrectomy was performed to clear dense vitritis and maintain oncologic control using a closed-system approach, melphalan irrigation (5 µg/mL), IVT topotecan, port-site cryotherapy, and silicone oil tamponade. The patient also received IVT vancomycin, ceftazidime, and voriconazole...The infection resolved, the tumor continued to regress, and no extraocular tumor spread was observed during 24 months of follow-up. Early, tailored vitrectomy may help preserve vision in severe endophthalmitis after IVT chemotherapy for retinoblastoma when strict oncologic precautions are maintained, with long-term follow-up required to monitor for tumor recurrence or extraocular spread."

Journal • Eye Cancer • Infectious Disease • Influenza • Ocular Infections • Ocular Inflammation • Ocular Melanoma • Oncology • Ophthalmology • Respiratory Diseases • Retinal Disorders • Retinoblastoma • Solid Tumor

Longitudinal dynamics of microbiological persistence and loss of detection in multidrug-resistant organisms: a survival analysis based on individual epidemiological surveillance trajectories. (PubMed, J Hosp Infect) - "Microbiological persistence in MDRO patients follows a dynamic, heterogeneous longitudinal pattern. Restricting this event to surveillance samples and classifying trajectory dynamics reveal phenomena undetectable through conventional approaches."

Journal • Infectious Disease

DVS: Dropless Pars Plana Vitrectomy Study (clinicaltrials.gov) - P4 | N=168 | Completed | Sponsor: Massachusetts Eye and Ear Infirmary | Recruiting ➔ Completed | Trial completion date: Jan 2027 ➔ Aug 2026

Trial completion • Trial completion date • Retinal Disorders

Familial Fecal Microbiota Transplant for the Treatment of Subjects With Autism Spectrum Disorders (clinicaltrials.gov) - P1 | N=10 | Not yet recruiting | Sponsor: ProgenaBiome | Trial completion date: Jul 2027 ➔ Jul 2028 | Trial primary completion date: Dec 2026 ➔ Jul 2027

Trial completion date • Trial primary completion date • Autism Spectrum Disorder • Genetic Disorders • Transplantation

Multifunctional calcium phosphate-bioactive glass composite cement with controlled degradation and local antibiotic delivery for bone regeneration. (PubMed, J Mater Chem B) - "The incorporation of mesoporous BG was associated with sustained, pseudo-Fickian release of vancomycin and ceftazidime over 28 days. Finally, an in vivo critical-sized rat cranial defect model confirmed that the composite achieves uniform, accelerated bone regeneration and substantial defect closure within 8 weeks. Together, these findings demonstrate that this degradation-associated delivery framework represents a promising strategy for managing complex, infection-prone bone defects."

Journal • Infectious Disease • ALPL

Current practices and unmet needs in the management of Clostridioides difficile infection in pediatric inflammatory bowel disease: A national survey. (PubMed, J Pediatr Gastroenterol Nutr) - "This nationwide survey highlights substantial unmet needs in CDI management in pediatric IBD, including variability in diagnostic strategies, lack of consensus on first-line therapy, and uncertainty regarding immunosuppressive management, supporting the need for evidence-based pediatric-specific guidelines."

Journal • Crohn's disease • Gastroenterology • Gastrointestinal Disorder • Immunology • Infectious Disease • Inflammation • Inflammatory Bowel Disease • Pediatrics • Transplantation • Ulcerative Colitis

Serotypes, sequence types, and erythromycin resistance of maternal colonizing group B Streptococcus: implications for neonatal early-onset disease prevention. (PubMed, Front Pediatr) - "All isolates were susceptible to penicillin, ampicillin and vancomycin, whereas erythromycin non-susceptibility reached 63.3%, comprising constitutive (40.0%), inducible (8.3%) and M (15.0%) phenotypes, with a further 3.3% showing the L phenotype. Among the women who had actually received clindamycin during labour, half were colonized by isolates against which clindamycin lacked in-vitro activity. These findings support routine D-testing of erythromycin non-susceptible maternal GBS isolates and reporting that states whether clindamycin is suitable for intrapartum prophylaxis."

Journal

Patient outcome according to drug exposure of systemic colistin in patients with ventilator-associated pneumonia caused by carbapenem-resistant gram-negative bacilli treated with systemic and aerosolized colistin (ERS 2026) - "High body mass index (P=0.041), lower estimated glomerular filtration rate (P=0.033), and concomitant vancomycin use (P=0.022) were associated with high colistin exposure. In patients with VAP caused by CRGNB treated with combined IV and AS colistin, the LD showed no statistically significant difference in clinical outcome compared to the HD."

Clinical • Gram negative • Infectious Disease • Pneumonia • Respiratory Diseases

SPARK: Exploring the Combination of Intracalvariosseous and Intravenous Antibiotics for Moderate to Severe Bacterial Meningitis (clinicaltrials.gov) - P=N/A | N=9 | Not yet recruiting | Sponsor: yilong Wang

New trial • CNS Disorders • Infectious Disease

Amphipathicity-driven optimization of substance P-derived antimicrobial peptides for infected wound healing. (PubMed, Bioorg Chem) - "In an S. aureus-infected mouse full-thickness wound model, SP-2 reduced recoverable bacterial burden more effectively than either SP-1 or vancomycin and improved wound repair. However, SP-2 exhibited concentration-dependent hemolysis and potential systemic toxicity at 60 mg/kg, indicating the need to further improve its therapeutic window. Together, this study provides a strategy for developing multifunctional short antimicrobial peptides from neuropeptide scaffolds for infected wound repair."

Journal • Hematological Disorders • Infectious Disease • Inflammation

Molecular characterization of PVL-positive methicillin-resistant Staphylococcus aureus (MRSA) isolates from skin and soft tissue infections in Alexandria, Egypt. (PubMed, Arch Microbiol) - "One isolate (2.6%; lineage CC1-MRSA-[V/VT + fus+ccrAB1]) was confirmed as vancomycin-resistant (VRSA)...Furthermore, the detection of a sporadic VRSA strain emphasizes the necessity of routine phenotypic susceptibility testing alongside molecular screening. The 100% concordance of LFAs supports their implementation as rapid, culture-based screening tools in laboratory diagnostic workflows to guide empirical antibiotic therapy and infection control."

Journal • Infectious Disease • FUS

Multisite Analysis of Vancomycin Concentration Predictions in a Bayesian Software in Adult and Pediatric Patients With and Without Acute Kidney Injury. (PubMed, Pharmacotherapy) - "Model predictiveness of vancomycin concentrations was worse in patients with AKI, especially in pediatrics and neonates, and generally less pronounced in persistent versus new-onset AKI. Further studies with denser pharmacokinetic sampling and elucidation of clinical implications of Bayesian-guided vancomycin dosing in AKI are needed."

Journal • Retrospective data • Acute Kidney Injury • Nephrology • Pediatrics • Renal Disease

Faecalibacterium prausnitzii EXL01 Strain for the prevention of multiple-recurrent Clostridioides difficile Infection. (PubMed, Gastroenterology) - P1/2 | "A single, well-characterized bacterial strain was associated with restoration of key microbiome functions and low recurrence rates in high-risk rCDI. These findings support precision microbiome therapeutics targeting ecosystem function rather than taxonomic complexity. Controlled trials are ongoing. (clinicaltrials.gov; NCT06306014)."

Journal • Infectious Disease • Inflammation • Inflammatory Bowel Disease • Transplantation

Isolation and Characterization of Lytic Bacteriophages Targeting Clinical Staphylococcus Other Than S. aureus. (PubMed, Lett Appl Microbiol) - "They strongly inhibited planktonic SOSA growth at MOI 10, with efficacy comparable to or better than vancomycin, and their genomes lacked lysogeny, virulence, or resistance genes. These phages display a lytic lifestyle and are candidates for targeted SOSA therapies. Future work will assess biofilm efficacy, antibiotic synergies, and in vivo performance."

Journal • Infectious Disease

Validation of an innovative tissue-cage/beads rabbit model for ex vivo determination of minimum levels of Staphylococcus aureus biofilm eradication. (PubMed, Eur J Clin Microbiol Infect Dis) - "Vancomycin, daptomycin, and rifampin MBEC90 values were 1.0, 1.5, and < 0.016 mg/L, respectively, and were significantly lower than those obtained against in vitro-formed biofilms. Compared with existing in vitro and in vivo studies, this innovative model of ex vivo determination of MBEC90 on in vivo-formed biofilm is likely to be more predictive of the in vivo anti-staphylococcal antibiofilm activity and requires a limited number of animals."

Journal • Preclinical • Infectious Disease

Randomized Placebo-Controlled, Biomarker-Stratified Phase Ib Microbiome Modulation in Melanoma: Impact of Antibiotic Preconditioning on Microbiome and Immunity. (PubMed, Cancer Discov) - P1b | "Fecal microbiota signatures were characterized at baseline; patients were stratified by high versus low Ruminococcaceae abundance prior to randomization to the SER-401 arm (oral vancomycin-preconditioning/SER-401 alone/nivolumab + SER-401), versus the placebo arm [placebo antibiotic/placebo microbiome modulation (PMM)/nivolumab + PMM (NCT03817125)]. This first-of-its-kind, placebo-controlled, randomized biomarker-driven microbiome modulation trial demonstrated that vancomycin + SER-401 and anti-PD-1 are safe in melanoma patients. Although limited by poor accrual during the pandemic, important insights were gained via translational analyses, suggesting that antibiotic preconditioning and interventional drug dosing regimens should be carefully considered when designing such trials."

Biomarker • IO biomarker • Journal • P1 data • Infectious Disease • Melanoma • Novel Coronavirus Disease • Oncology • Solid Tumor

Characterization of the microbial resistome in a prospective trial of CBM588 in metastatic renal cell carcinoma (mRCC) offers mechanism for interplay between antibiotic (abx) use and immune checkpoint inhibitor (ICI) activity. (ASCO 2022) - P1 | " Pts with newly diagnosed mRCC with clear cell and/or sarcomatoid histology and intermediate/high risk disease per IMDC criteria were randomized to nivolumab/ipilimumab (nivo/ipi) or nivo/ipi/CBM588 in a 1:2 ratio...More specifically, nivo/ipi/CBM588 treatment led to a significant reduction in fosfomycin RGs and nitroimidazole (e.g., metronidazole) RGs in both pts with R (p = 0.019 and 0.042, respectively) and NR (p = 0.031 and p = 0.031, respectively). A multitude of other clinically relevant abx RGs were downregulated in pts receiving CBM588, including those mediating resistance to glycopeptide (e.g., vancomycin) and lincosamide (e.g., clindamycin) abx... In the first interrogation of the resistome in mRCC, we demonstrate that CBM588 decreases abx RGs associated with multiple commonly used classes of abx. Abx clear commensals and increase pathogenic (abx resistant) bacteria in the gut. Based on our data, we formulate the hypothesis that combining abx with CBM588..."

Checkpoint inhibition • Clinical • Genito-urinary Cancer • Immune Modulation • Inflammation • Lung Cancer • Oncology • Renal Cell Carcinoma • Sarcoma • Solid Tumor

Looking Beyond Clostridioides Difficile: Persistent Diarrhea Unmasking PembrolizumabâInduced ImmuneâMediated Colitis (ACG 2026) - "She continued to have 5â7 loose bowel movements daily and crampy abdominal pain despite oral vancomycin and a switch to fidaxomicin after 5 days...Disease was refractory to corticosteroids and infliximab but ultimately responded to upadacitinib...Figure: Figure 2. Gross bloody diarrheal stool and representative colonoscopic images from the ascending, descending, and sigmoid colon demonstrating diffuse erythema, friability, and ulceration, consistent with severe pancolitis due to immuneâmediated colitis in the setting of pembrolizumab therapy."

Gastroenterology • Gastrointestinal Disorder • Immunology • Infectious Disease • Lung Cancer • Solid Tumor

Vancomycin-Resistant, Thermotolerant Enterococcus faecalis and Enterococcus faecium in Ready-to-Eat Beef Luncheon and Sausage. (PubMed, Foods) - "Antimicrobial susceptibility testing demonstrated widespread multidrug resistance, with high resistance rates to β-lactams, tetracycline (94%), vancomycin (62.5%), and rifampin (91%). These findings highlight RTE meat products collected from Mansoura city as potential reservoirs of thermotolerant, multidrug-resistant enterococci, raising a potential public health concern and emphasizing the need for improved food safety measures and further nationwide studies. Although direct epidemiological links between foodborne isolates and clinical infections were not established, the presence of such strains raises a potential public health concern and underscores the need for improved food safety measures and further epidemiological investigations."

Journal • Infectious Disease

Bacterial Contamination in Stored Blood for Transfusion and Associated Infectious Risks Among Patients with Cancer at Mbarara Regional Referral Hospital, in Uganda. (PubMed, J Blood Med) - "The isolates exhibited variable resistance to erythromycin, clindamycin, teicoplanin, vancomycin, tetracycline, nitrofurantoin, rifampicin, and trimethoprim-sulfamethoxazole. The four bacterial isolates were resistant to common antibiotics, which poses a risk of transmission of antibiotic-resistant strains to immunocompromised recipients with cancer. Notably, there was no infectious risk posed post-transfusion presumably due to the concurrent antibiotic therapy."

Journal • Infectious Disease • Oncology • Renal Cell Carcinoma

Antimicrobial resistance in Noma control: a costly neglect within existing neglect. (PubMed, Trop Med Health) - "AMR risks reversing gains in Noma control, and treatment centers may become AMR amplification sites without stewardship. Given limited microbiology data, we recommend adding AMR indicators to WHO and national Noma strategies, integrating anaerobic AMR surveillance at sentinel sites, generating Noma-specific antibiograms, and mandating antimicrobial stewardship in Noma programs. Mainstreaming AMR in Noma research and policy is essential to preserve therapeutic options."

Journal • Review

Could Less Be More? Reconsidering Immunosuppressive Escalation in Refractory Immune Effector Cell-Associated Enterocolitis Complicated by Recurrent C. difficile Infection (ACG 2026) - "Case Description/ A 73-year-old male with multiple myeloma (MM) refractory to several lines of therapy underwent CAR-T infusion with ciltacabtagene autoleucel, developing biopsy-proven disease progression with infiltrative extramedullary disease of the GI tract...difficile PCR returned positive with negative toxin, creating diagnostic uncertainty in the setting of suspected IEC-AE; fidaxomicin was initiated...Diarrhea worsened despite two doses each of cyclophosphamide and vedolizumab...Concurrently, vancomycin was initiated for repeat C. difficile infection and valganciclovir for cytomegalovirus viremia. Ruxolitinib was given for refractory IEC-AE alongside fludarabine for the recurrent and progressive MM involving the GI tract...(A) Upper endoscopy demonstrating diffuse nodular mucosa involving the duodenal bulb and 1st and 2nd portions of the duodenum. (B) Colonoscopy showing grossly normal ascending, transverse, and descending colon despite biopsy-confirmed IEC-AE."

Cytomegalovirus Infection • Gastroenterology • Gastrointestinal Disorder • Hematological Malignancies • Immunology • Infectious Disease • Inflammatory Bowel Disease • Multiple Myeloma

Volumetric Microsampling for Patient-Centric Therapeutic Drug Monitoring in Clinical Pharmacology: A Scoping Review. (PubMed, J Clin Pharmacol) - "Fixed conversion factors performed well for lacosamide and levetiracetam but were less reliable for lamotrigine at high concentrations. Several analyte-matrix combinations, including cefepime, vancomycin, meropenem, paclitaxel, abiraterone, and mitotane, did not consistently meet agreement criteria. Volumetric microsampling can support patient-centered drug monitoring when validated for the specific analyte, matrix, device, and clinical application. Future research should prioritize drug-specific optimization, multicenter validation, standardized conversion reporting, and integration with MIPD platforms."

Journal • Review

Methicillin resistance and antimicrobial non-susceptibility trends among Staphylococcus aureus clinical isolates in Aseer, Saudi Arabia (2013-2024): A retrospective laboratory-based surveillance study. (PubMed, PLoS One) - "In this single-center Aseer surveillance, MRSA became the majority of S. aureus during 2013-2024 and showed broad multidrug non-susceptibility, while vancomycin and daptomycin retained full in vitro activity. These local findings support sustained laboratory-based surveillance, Aseer-tailored empirical and stewardship guidance, and confirmatory testing of the emerging low-level linezolid non-susceptibility signal."

Journal • Retrospective data • Infectious Disease

Infection risk in myelodysplastic syndromes is dynamic and immune driven. (PubMed, Blood Adv) - "Among azacitidine-treated patients, 71.4% experienced infection-related hospitalization, with nearly three-quarters occurring within the first six cycles, identifying a critical early vulnerability window...We observed a concerning shift in antimicrobial resistance, with 14% of Gram-negative infections producing extended-spectrum beta-lactamases, 21% of Pseudomonas aeruginosa isolates resistant to piperacillin-tazobactam, and vancomycin-resistant enterococci prevalence increasing from 14% to 46%. Together, these findings identify infection in MDS as a dynamic, prognostically important complication driven by cytopenia, treatment, and immune dysfunction. This supports time-adapted risk stratification, targeted prevention, and antimicrobial stewardship, particularly during early treatment and high-risk disease phase."

Journal • Hematological Disorders • Hematological Malignancies • Infectious Disease • Myelodysplastic Syndrome • Neutropenia • Oncology • Transplantation • TP53